'Double-Hit' cytogenetic status may not be predicted by baseline clinicopathological characteristics and is highly associated with overall survival in B cell lymphoma patients

British Journal of Haematology

Volumn 166, Issue 3, 2014, Pages 369-374

  Landsburg, Daniel J ^a   Nasta, Sunita D ^a   Svoboda, Jakub ^a   Morrissette, Jennifer J D ^b   Schuster, Stephen J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

'Double Hit' lymphoma; Chemotherapy; Fluorescence in situ hybridization; MYC; Survival

Indexed keywords

LACTATE DEHYDROGENASE;

ADULT; AGE; ARTICLE; BCL2 GENE; BCL6 GENE; CANCER STAGING; CLINICAL FEATURE; CONTROLLED STUDY; CYTOGENETICS; DOUBLE HIT B CELL LYMPHOMA; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE REARRANGEMENT; HISTOLOGY; HUMAN; INTERNATIONAL PROGNOSTIC INDEX; KARYOTYPING; LACTATE DEHYDROGENASE BLOOD LEVEL; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; METAPHASE; ONCOGENE MYC; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL;

'DOUBLE-HIT' LYMPHOMA; CHEMOTHERAPY; FLUORESCENCE IN SITU HYBRIDIZATION; MYC; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; CHROMOSOME ABERRATIONS; GENE REARRANGEMENT; HUMANS; LYMPHOMA, B-CELL; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; TRANSLOCATION, GENETIC; YOUNG ADULT;

EID: 84904061091     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12901     Document Type: Article

References (24)

1. Aukema, S.M., Siebert, R., Schuuring, E., van Imhoff, G.W., Kluin-Nelemans, H.C., Boerma, E.J. & Kluin, P.M. (2011) Double-hit B-cell lymphomas. Blood, 117, 2319-2331.
2. Aukema, S.M., Kreuz, M., Kohler, C.W., Rosolowski, M., Hasenclever, D., Hummel, M., Kuppers, R., Lenze, D., Ott, G., Pott, C., Richter, J., Rosenwald, A., Szczepanowski, M., Schwaenen, C., Stein, H., Trautmann, H., Wessendorf, S., Trumper, L., Loeffler, M., Spang, R., Kluin, P.M., Klapper, W. & Siebert, R. (2014) Biologic characterization of adult MYC-translocation positive mature B-cell lymphomas other than molecular Burkitt lymphoma. Haematologica, 99, 726-735.
3. Barrans, S., Crouch, S., Smith, A., Turner, K., Owen, R., Patmore, R., Roman, E. & Jack, A. (2010) Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. Journal of Clinical Oncology, 28, 3360-3365.
4. Cheson, B.D., Pfistner, B., Juweid, M.E., Gascoyne, R.D., Specht, L., Horning, S.J., Coiffier, B., Fisher, R.I., Hagenbeek, A., Zucca, E., Rosen, S.T., Stroobants, S., Lister, T.A., Hoppe, R.T., Dreyling, M., Tobinai, K., Vose, J.M., Connors, J.M., Federico, M. & Diehl, V. (2007) Revised response criteria for malignant lymphoma. Journal of Clinical Oncology, 25, 579-586.
5. Cory, S., Vaux, D.L., Strasser, A., Harris, A.W. & Adams, J.M. (1999) Insights from Bcl-2 and Myc: malignancy involves abrogation of apoptosis as well as sustained proliferation. Cancer Research, 59, 1685s-1692s.
6. Foot, N.J., Dunn, R.G., Geoghegan, H., Wilkins, B.S. & Neat, M.J. (2011) Fluorescence in situ hybridisation analysis of formalin-fixed paraffin-embedded tissue sections in the diagnostic work-up of non-Burkitt high grade B-cell non-Hodgkin's lymphoma: a single centre's experience. Journal of Clinical Pathology, 64, 802-808.
7. Gandhi, M., Petrich, A.M., Cassaday, R.D., Press, O.W., Shah, K., Whyman, J., Lansigan, F., Zelenetz, A.D., Shah, N., Fenske, T.S., Hernandez-Ilizaliturri, F.J., Lee, L.X., Barta, S.K., Karmali, R., Melinamani, S., Adeimy, C., Smith, S.E., Vose, J.M., Dalal, N., Nabhan, C., Peace, D., Jovanvoic, B., Sohani, A.R., Evens, A.M., Castillo, J.J. & Abramson, J.S. (2013) Impact of induction regimen and consolidative stem cell transplantation in patients with Double Hit Lymphoma (DHL): a large multicenter retrospective analysis. Blood, 122, 640.
8. Green, T.M., Young, K.H., Visco, C., Xu-Monette, Z.Y., Orazi, A., Go, R.S., Nielsen, O., Gadeberg, O.V., Mourits-Andersen, T., Frederiksen, M., Pedersen, L.M. & Moller, M.B. (2012) Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, Doxorubicin, vincristine, and prednisone. Journal of Clinical Oncology, 30, 3460-3467.
9. Howlett, C., Goy, A., Zielonka, T., Pecora, A.L., Feldman, T., Rowley, S.D., Donato, M.L., Timberg, M., Gadaleta, G., Vesole, D.H., Bhattacharyya, P.M., Chow, K.F., Faroqui, R., Rosario, M. & Mato, A.R. (2013) Dose intensive induction followed by allogeneic stem cell transplantation more than doubles progression-free and overall survival in "Double-Hit" Lymphoma (DHL). Blood, 122, 2141.
10. Johnson, N.A., Savage, K.J., Ludkovski, O., Ben-Neriah, S., Woods, R., Steidl, C., Dyer, M.J., Siebert, R., Kuruvilla, J., Klasa, R., Connors, J.M., Gascoyne, R.D. & Horsman, D.E. (2009) Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood, 114, 2273-2279.
11. Johnson, N.A., Slack, G.W., Savage, K.J., Connors, J.M., Ben-Neriah, S., Rogic, S., Scott, D.W., Tan, K.L., Steidl, C., Sehn, L.H., Chan, W.C., Iqbal, J., Meyer, P.N., Lenz, G., Wright, G., Rimsza, L.M., Valentino, C., Brunhoeber, P., Grogan, T.M., Braziel, R.M., Cook, J.R., Tubbs, R.R., Weisenburger, D.D., Campo, E., Rosenwald, A., Ott, G., Delabie, J., Holcroft, C., Jaffe, E.S., Staudt, L.M. & Gascoyne, R.D. (2012) Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. Journal of Clinical Oncology, 30, 3452-3459.
12. Li, S., Lin, P., Fayad, L.E., Lennon, P.A., Miranda, R.N., Yin, C.C., Lin, E. & Medeiros, L.J. (2012) B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome. Modern Pathology, 25, 145-156.
13. Li, S., Lin, P., Young, K.H., Kanagal-Shamanna, R., Yin, C.C. & Medeiros, L.J. (2013) MYC/BCL2 double-hit high-grade B-cell lymphoma. Advances in Anatomic Pathology, 20, 315-326.
14. Mason, K.D., Vandenberg, C.J., Scott, C.L., Wei, A.H., Cory, S., Huang, D.C. & Roberts, A.W. (2008) In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas. Proceedings of the National Academy of Sciences of the United States of America, 105, 17961-17966.
15. Mato, A., Feldman, T., Zielonka, T., Singavi, A., Gadaletta, G., Waksmundzki, K., Bhattacharyya, P., Chow, K.F., Yang, X., Panush, D., Agress, H., Rosario, M., Howlett, C., Pecora, A. & Goy, A. (2013) Rituximab, cyclophosphamide-fractionated, vincristine, doxorubicin and dexamethasone alternating with rituximab, methotrexate and cytarabine overcomes risk features associated with inferior outcomes in treatment of newly diagnosed, high-risk diffuse large B-cell lymphoma. Leukaemia & Lymphoma, 54, 2606-2612.
16. Oki, Y., Westin, J.R., Vega, F., Chuang, H., Fowler, N., Neelapu, S., Hagemeister, F.B., McLaughlin, P., Kwak, L.W., Romaguera, J.E., Fanale, M., Younes, A., Rodriguez, M.A., Orlowski, R.Z., Wang, M., Ouzounian, S.T., Samaniego, F. & Fayad, L. (2013a) Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma. British Journal of Haematology, 163, 611-620.
17. Oki, Y., Noorani, M., Davis, R.E., Neelapu, S.S., Rodriguez, A., Hagemeister, F.B., Fowler, N., Wang, M., Fanale, M.A., Samaniego, F., Dabaja, B.S., Pinnix, C., Kwak, L.W., Romaguera, J.E., Khouri, I., Westin, J.R. & Fayad, L.E. (2013b) Double hit lymphoma: M.D. Anderson experience. Blood, 122, 1776.
18. Pedersen, M.O., Gang, A.O., Poulsen, T.S., Knudsen, H., Lauritzen, A.F., Nielsen, S.L., Gang, U.O. & Norgaard, P. (2012) Double-hit BCL2/MYC translocations in a consecutive cohort of patients with large B-cell lymphoma - a single centre's experience. European Journal of Haematology, 89, 63-71.
19. Perry, A.M., Alvarado-Bernal, Y., Laurini, J.A., Smith, L.M., Slack, G.W., Tan, K.L., Sehn, L.H., Fu, K., Aoun, P., Greiner, T.C., Chan, W.C., Bierman, P.J., Bociek, R.G., Armitage, J.O., Vose, J.M., Gascoyne, R.D. & Weisenburger, D.D. (2014) MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab. British Journal of Haematology, 165, 382-391.
20. Savage, K.J., Johnson, N.A., Ben-Neriah, S., Connors, J.M., Sehn, L.H., Farinha, P., Horsman, D.E. & Gascoyne, R.D. (2009) MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood, 114, 3533-3537.
21. Snuderl, M., Kolman, O.K., Chen, Y.B., Hsu, J.J., Ackerman, A.M., Dal Cin, P., Ferry, J.A., Harris, N.L., Hasserjian, R.P., Zukerberg, L.R., Abramson, J.S., Hochberg, E.P., Lee, H., Lee, A.I., Toomey, C.E. & Sohani, A.R. (2010) B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma. American Journal of Surgical Pathology, 34, 327-340.
22. Thomas, D.A., Cortes, J., O'Brien, S., Pierce, S., Faderl, S., Albitar, M., Hagemeister, F.B., Cabanillas, F.F., Murphy, S., Keating, M.J. & Kantarjian, H. (1999) Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia. Journal of Clinical Oncology, 17, 2461-2470.
23. Vandenberg, C.J. & Cory, S. (2013) ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia. Blood, 121, 2285-2288.
24. Visco, C., Tzankov, A., Xu-Monette, Z.Y., Miranda, R.N., Tai, Y.C., Li, Y., Liu, W.M., d'Amore, E.S., Montes-Moreno, S., Dybkaer, K., Chiu, A., Orazi, A., Zu, Y., Bhagat, G., Wang, H.Y., Dunphy, C.H., His, E.D., Zhao, X.F., Choi, W.W., Zhao, X., van Krieken, J.H., Huang, Q., Ai, W., O'Neill, S., Ponzoni, M., Ferreri, A.J., Kahl, B.S., Winter, J.N., Go, R.S., Dirnhofer, S., Piris, M.A., Moller, M.B., Wu, L., Medeiros, L.J. & Young, K.H. (2013) Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study. Haematologica, 98, 255-263.